Popular terms

G Protein topics
Antibodies
Nucleic Acid
G Proteins
Nucleic Acids
Amino Acid
Polypeptide
Protein A Affinity Chromatography
Chromatography
Chromatograph
Liver Metastasis
Membrane Protein
Colorectal Carcinoma
Rectal Carcinoma
Prophylactic
Glycoprotein

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

G Protein patents



      

This page is updated frequently with new G Protein-related patent applications.




Date/App# patent app List of recent G Protein-related patents
04/28/16
20160115246 
 Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9 patent thumbnailnew patent Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitor.
Regeneron Pharmaceuticals, Inc.


04/28/16
20160115211 
 Compositions and methods for regulating angiogenesis and cholesterol and treating dyslipidemia, atherosclerosis, cancer and inflammatory conditions patent thumbnailnew patent Compositions and methods for regulating angiogenesis and cholesterol and treating dyslipidemia, atherosclerosis, cancer and inflammatory conditions
The invention provides pharmaceutical compounds and formulations comprising nucleic acids and polypeptides for regulating (including upregulating or inhibiting) the expression of apoa-1 binding protein (apoaibp, aibp, or ai-bp), and methods for making and using them. In alternative embodiments, apoaibp-inhibiting pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to stimulate tissue revascularization, e.g., supporting or stimulating revascularization of heart tissue, e.g., after a cardiac ischemia.
The Regents Of The University Of California


04/28/16
20160115210 
 Colorimetric and fluorescent proteins patent thumbnailnew patent Colorimetric and fluorescent proteins
The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.. .
Board Of Trustees Of Michigan State University


04/28/16
20160114036 
 Composition for stabilizing protein and pharmaceutical formulation comprising the same patent thumbnailnew patent Composition for stabilizing protein and pharmaceutical formulation comprising the same
The present invention relates to a composition for stabilizing tnfα-binding protein exhibiting physiological activity, and more specifically, to a composition for stabilizing protein including basic amino acid and sugar and/or ammonium salt, a pharmaceutical formulation including the same, and a method for stabilizing tnfα-binding protein. The formulation including basic amino acid; and sugar and/or ammonium salt according to the present invention effectively inhibits aggregation, denaturation and oxidation of tnfα-binding protein used for treating various diseases, for example, an anti-tnf-alpha antibody, such that the protein is capable of being preserved and stored for a long time, which is widely usable and effective in a medical field using tnfα-binding protein, for example, an anti-tnf-alpha antibody..
Alteogen Inc.


04/28/16
20160113937 
 Discovery of fda-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening patent thumbnailnew patent Discovery of fda-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening
Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (fabp4). The present invention provides a novel use of levofloxacin as an inhibitor of fabp4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases.
The Chinese University Of Hong Kong


04/21/16
20160110452 
 Method and  pairing music and food selections patent thumbnailMethod and pairing music and food selections
A system and method enable the selection of musical recordings for pairing with a food serving, possibly an entrée, a dessert or a beverage, for the purpose of increasing the enjoyment of a given meal. A plurality of factors for specific meal components such as entree, including protein type, method of cooking, amount of spice, and type of sauce are used to determine a specific numerical value for a meal; dessert, including content of cacao, sweetener and content of sweetener, ambient temperature at service and dairy content; and beverage, including but not limited to alcohol content, acidity, body, dryness, lingering quality, and ibu.

04/21/16
20160110450 
 Method and  pairing music and food selections patent thumbnailMethod and pairing music and food selections
A system and method enable the selection of musical recordings for pairing with a food serving, possibly an appetizer, a main course, a dessert or a beverage, for the purpose of increasing the enjoyment of a given meal. A plurality of factors for specific meal components such as entree, including protein type, method of cooking, amount of spice, side dish component and type of sauce are used to determine a specific numerical value for a meal; appetizer including protein type, bread and dough content, method of cooking and spice level; dessert, including content of cacao, sweetener and content of sweetener, ambient temperature at service and dairy content; and beverage, including but not limited to alcohol content, acidity, body, dryness, lingering quality, and ibu.

04/21/16
20160109424 
 Swath™ data-independent acquisition technology for the detection of host cell protein contaminants in biotherapeutics protein products patent thumbnailSwath™ data-independent acquisition technology for the detection of host cell protein contaminants in biotherapeutics protein products
Systems and methods are provided for detecting host cell contaminants in a protein biotherapeutic product using sequential windowed acquisition tandem mass spectrometry. Sequential windowed acquisition is performed on a protein biotherapeutic product sample by sequentially stepping a precursor mass window across a mass range, fragmenting transmitted precursor ions of each stepped precursor mass window, and analyzing product ions produced from the fragmented transmitted precursor ions.

04/21/16
20160108421 
 Method for producing stress tolerant transgenic plant by silencing a gene encoding calcium-dependent lipid-binding protein with c2 domain and applications of the same patent thumbnailMethod for producing stress tolerant transgenic plant by silencing a gene encoding calcium-dependent lipid-binding protein with c2 domain and applications of the same
A method for silencing rice plant, includes the steps of: identifying a first nucleotide sequence from oryza sativa, wherein the first nucleotide sequence is homologous to a ca2+-dependent lipid-binding gene of arabidopsis thaliana (atclb gene); cloning the first nucleotide sequence to a first vector to form a first recombinant vector, such that the first recombinant vector contains a first insert of the first nucleotide sequence; and transfer the first insert in the first recombinant vector to a second vector to form a second recombinant vector, such that the second recombinant vector contains a second insert of the first nucleotide sequence. The second recombinant vector, when being introduced to oryza sativa plant cells, is capable of silencing the first nucleotide sequence of the oryza sativa plant cells, such that the oryza sativa plant cells are tolerant to an abiotic stress..

04/21/16
20160106850 
 Methods and compositions for wound treatment patent thumbnailMethods and compositions for wound treatment
The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.. .

04/14/16
20160102362 

Gep5 model for multiple myeloma


The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (eno1), fatty acid binding protein 5 (fabp5), thyroid hormone receptor interactor 13 (trip 13), transgelin 2 (tagln2), and replication factor c (activator 1) 4 (rfc4) in a biological sample isolated from the subject.

04/14/16
20160102301 

Protein, manufacturing same, and evaluating protein activity


The present invention relates to a method for producing a protein, comprising an inspection process, wherein the inspection process comprises: a step of approximating an infrared absorption band derived from a protein appearing around 1500 to 1600 cm−1 or around 1600 to 1700 cm−1 in an infrared absorption spectrum of the protein, by one or more normal distributions, a step of calculating an index value indicating a degree of broadening of the infrared absorption band based on the normal distributions, and a step of comparing the index value with a predetermined threshold to select, as a good-quality product, a protein having a degree of broadening of the infrared absorption band that is smaller than the threshold.. .

04/14/16
20160102150 

Plasma kallikrein binding proteins


Plasma kallikrein binding proteins and methods of using such proteins are described.. .

04/14/16
20160102054 

Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)


Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of src homology 2-domain containing protein tyrosine phosphatase-2..

04/14/16
20160101161 

Anti-viral therapeutic for infection of the eye


The present disclosure provides novel compositions and methods for treating an infection of the eye resulting from an infection of a member of the picornavirdae virus family. In particular, the present disclosure provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen, such as a virus.

04/14/16
20160101159 

Methods and compositions for promiting glucose homeostasis


A method of reducing blood glucose in a subject has been developed. In preferred embodiments, the method involves administering to the subject a specific activator of endogenous mitogen-activated protein kinase kinase 6 (mkk3), mitogen-activated protein kinase kinase 6 (mkk4), mitogen-activated protein kinase kinase 6 (mkk6), p38 mitogen-activated protein kinase (p38mapk), mitogen-activated kinase-activated protein kinase 2 (mk2), or a combination thereof, in an effective amount to reduce blood glucose in a subject.

04/07/16
20160097765 

Electrochemiluminescence detecting an analyte in a liquid sample and analysis system


An electrochemiluminescence method of detecting an analyte in a liquid sample and a corresponding analysis system. An analyte in a liquid sample is detected by first providing a receptacle containing a fluid comprising protein coated magnetic microparticles to a stirring unit.
Roche Diagnostics Operations, Inc.


04/07/16
20160097053 

Yeast promoters from pichia pastoris


In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from pichia pastoris wherein the nucleic acids have promoter activity are described.
Keck Graduate Institute Of Applied Life Sciences


04/07/16
20160097050 

Devices and methods for display of encoded peptides, polypeptides, and proteins on dna


A novel method for displaying proteins and peptides is disclosed in which individual proteins or peptides remain associated with the dna encoding them. Proteins or peptides can be generated by in vitro translation of dna templates, either free in solution or arrayed on a solid support, such that the proteins or peptides remain immobilized on their dna templates.
The Board Of Trustees Of The Leland


04/07/16
20160096800 

Modulators of the eif2alpha pathway


Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eif2α phosphorylation, the integrated stress response (isr), and the unfolded protein response (upr); for treating diseases; for increasing protein production, and for improving long-term memory.. .
The Regents Of The University Of California


04/07/16
20160095917 

Dps fusion proteins for use in vaccines and diagnostics


Novel nanoparticle fusion proteins comprising proteins or peptides fused to dps (dna binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.. .
Kj Biosciences Llc


04/07/16
20160095313 

Antimicrobial compositions and methods


The present invention is generally related to a product and process to reduce the microbial contamination on organic matter, such as processed meat, fruits and vegetables, plant parts, inanimate surfaces such as textiles and stainless steel, and in the mouth or on dental products. In particular, the invention is related to a product and process to disinfect surfaces using an antimicrobial composition containing an antimicrobial lipid, an enhancer selected from the group consisting of bacteriocins, antimicrobial enzymes, sugars, sugar alcohols, iron-binding proteins and derivatives thereof, siderophores, and combinations thereof, and optionally a surfactant..
3m Innovative Properties Company


03/31/16
20160091502 

Fibrosis biomarker assay


Methods of diagnosis or of quantitation of fibrosis are provided that comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of the measure in the patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a contacting protein fragments naturally present in the sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to the immunological binding partner to measure therein protein fragments comprising the neo-epitope.
Nordic Bioscience A/s


03/31/16
20160090414 

Binding proteins specific for insulin-like growth factors and uses thereof


Binding proteins, such as antibodies directed to igf-ii with cross-reactivity to igf-i and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the igf-ii with cross-reactivity to igf-i are disclosed.
Medimmune Limited


03/31/16
20160090411 

Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers


The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158p1d7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158p1d7 and variants thereof.. .
Agensys, Inc.


03/31/16
20160090404 

Modified biotin-binding protein, fusion proteins thereof and applications


The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen.
Children's Medical Center Corporation


03/31/16
20160090400 

Antibody like protein


A general method and recombinant nucleic acid sequences, by means which the method selects a recombinant protein containing an fha domain for binding a target molecule from a library proteins with a high-throughput method of creating protein variations within the fha domain in non-conserved or non-structural sequences of the fha scaffold, and the library may also be in the form of a phagemid or phage library wherein the alp nucleic acid sequence is inserted into a vector capable of allowing the vector and expressed alp protein from being virally packaged, and the recombinant nucleic acid sequences which are randomly mutated at varying non-conserved or non-structural fha domain sequences.. .

03/31/16
20160089445 

Derivatisation of biological molecules


The polymers are particularly suitable for derivatising proteins, such as interferon-α.. .

03/31/16
20160089418 

Therapeutic compositions for neutralizing type i interferons, and methods of use


The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing type i interferons in a mammal. The compositions contain a soluble orthopoxvirus ifn-binding protein that is modified to remove the cell-binding region, and that specifically binds to type i ifns, and a pharmaceutically acceptable carrier or excipient.
The United States Of America As Represented By The Secretary Of The Army, Of Behalf Of The United


03/24/16
20160084845 

Compositions and methods for detecting s-nitrosylation and s-sulfinylation


The present invention relates to methods for detecting protein s-sulfinylation and s-sulfinylation within thiol groups in proteins, metabolites, or materials.. .
The Regents Of The University Of Michigan


03/24/16
20160083707 

Plant lectins as carriers of associated drug substances into animal and human cells


The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (b subunits) of plant “ab toxins” (ptb lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation.
Biostrategies Lc


03/24/16
20160083452 

Isolation and purification of antibodies using protein a affinity chromatography


Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise ph viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably protein a affinity, ion exchange chromatography, and hydrophobic chromatography.
Abbvie Inc.


03/24/16
20160083392 

Fused heterocyclic compounds as protein kinase inhibitors


The invention is fused heterocyclic compounds of formula (i), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including bruton's tyrosine kinase (btk), and for treating disorders mediated thereby..
Beigene, Ltd.


03/24/16
20160083337 

Crystal structure of bifunctional transglycosylase pbp1b from e. coli and inhibitors thereof


The crystal structure at 2.16 Å resolution of the full-length bacterial bifunctional transglycosylase penicillin-binding protein 1b (pbp1b) from escherichia coli, in complex with its inhibitor moenomycin, is provided. The atomic coordinates of the complex as well as the moenomycin binding site are provided.
Academia Sinica


03/24/16
20160082294 

Pulsating electromagnetic and ultrasound therapy for stimulating targeted heat shock proteins and facilitating protein repair


A system and method are disclosed for stimulating activation of heat shock proteins and facilitating protein repair in cells and tissues in order to take advantage of the remediative and restorative nature of the increased heat shock protein activation or production and the facilitation of protein repair, while not damaging the cells and tissues. This is accomplished by treating a specified target area with an ultrasound or electromagnetic radiation source which is pulsed and applied or focused to one or more small areas in order to achieve the necessary temperature rise or sufficiently stress the cells and tissue to stimulate heat shock protein production or activation and facilitate protein repair, while allowing the temperature to decay sufficiently quickly so as not to damage or destroy the treated tissue..
Ojai Retinal Technology, Llc


03/24/16
20160082083 

Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity


Insulin-like growth factor binding proteins (igfbps) and variants thereof, including igfbp-1, igfbp-2, igfbp-3, igfbp-4, igfbp-5, igfbp-8 and the c-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin b activity.. .
National Research Council Of Canada


03/24/16
20160081348 

Decontamination solution and its use for denaturation, modification, degradation, solubilisation and removal of proteins, nucleic acid molecules and microorganisms


The invention concerns a three component system comprising surface-active substances, vitamins and metal ions for efficient destruction and removal of contaminating proteins, nucleic acids and microorganisms from surfaces like for example laboratory benches, floors, equipment and instruments. These non-corrosive and non-toxic solutions for removal of proteins, nucleic acids and microorganisms are applied by spraying, rubbing or immersion of contaminated surfaces thereby destroying, solubilizing inactivating and removing proteins and nucleic acids.
Multibind Biotec Gmbh


03/17/16
20160077113 

Methods of identifying candidate compounds of the human g protein-coupled receptor, gpr50, as modulators of body mass or adiposity


The present invention relates to methods of using a g protein-coupled receptor (gpcr) to screen one or more candidate compounds as a modulator of body mass or of adiposity or of percentage body fat in a subject or as a pharmaceutical agent for obesity and conditions related thereto. Inverse agonists and antagonists of the invention are useful as therapeutic agents for the prevention or treatment of obesity and conditions related thereto, including hypertension, insulin resistance, metabolic syndrome, type 2 diabetes, dyslipidemia, atherosclerosis, coronary heart disease, and stroke.
Arena Pharmaceuticals, Inc.


03/17/16
20160076074 

Probes and assays for measuring e3 ligase activity


Provided herein is technology relating to the biological process of protein ubiquitination and particularly, but not exclusively, to compositions and methods for studying protein ubiquitination and developing therapeutics to modulate protein ubiquitination.. .
Northwestern University


03/17/16
20160076052 

Design synthetic genes


The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a gc content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a gc content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes..
Jnc Corporation


03/17/16
20160075773 

Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration


The present application describes rgm a binding proteins, particularly monoclonal antibodies, and in particular cdr grafted, humanized versions thereof, which have the ability to bind to rgm a and prevent binding of rgm proteins to rgm a receptor and other rgm a binding proteins, and therefore neutralize the function of rgm a, for use in the treatment of retinal nerve fiber layer (rnfl) degeneration as well as methods of therapeutically or prophylactically treating a mammal against rnfl degeneration.. .
Abbvie Deutschland Gmbh & Co. Kg


03/17/16
20160075747 

Method for producing protein


The inventors of the present application newly discovered sf3b4 protein as a protein that specifically interacts with the coiled-coil domain of p180 protein, a responsible region for its capability of promoting polysome formation, and which is capable of promoting mrna localization to an endoplasmic reticulum (er). The inventors also found that, in cells capable of highly expressing both p180 protein and a protein promoting mrna localization to an endoplasmic reticulum (er) (e.g., sf3b4 protein), the mrna localization to the endoplasmic reticulum can be significantly elevated so that the secretory capacity in cultured cells can be enhanced.

03/17/16
20160075744 

Dna-binding protein using ppr motif, and use thereof


(helix a)-x-(helix b)-l  (formula 1). .

03/17/16
20160075743 

Methods and materials for encapsulating proteins


The invention provides a method for encapsulating a protein of interest, the method comprising the step of expressing a fusion protein comprising an n-terminal region of a rearrangement hot spot (rhs)-repeat-containing protein fused to the protein of interest. The invention further provides applications for the encapsulation, release and delivery of the protein of interest.
Agresearch Ltd


03/17/16
20160075695 

Benzimidazole derivatives as bromodomain inhibitors


This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (brd4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of formula (i) wherein r1, r1b, r2a, r2b, r3, r4a, r4b, and r5 are described herein..
Gilead Sciences, Inc.


03/17/16
20160074511 

Recombinant self-assembling protein comprising target-oriented peptide and use thereof


The present invention relates to a recombinant self-assembled protein comprising a target-oriented peptide and a use thereof. The recombinant self-assembled protein according to the present invention, comprising a target-oriented peptide, does not require an additional process for providing target-orientedness, and is thus capable of delivering a desired drug to a target tissue or target cell without using additives, such as chemical binders or stabilizers; therefore, the protein can be used for photothermal therapy, drug delivery, imaging, or the like.
Korea University Research And Business Foundation


03/17/16
20160074486 

Therapeutic composition with a botulinum neurotoxin


The present invention pertains to pharmaceutical compositions which comprise botulinum toxin from clostridium botulinum. The pharmaceutical compositions of the instant invention are not only free of a mammalian derived proteinaceous stabilizing agent but are free of any stabilizing protein..
Merz Pharma Gmbh & Co. Kgaa


03/17/16
20160074373 

Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs


Compositions and methods concern organic molecules that bind to human atox1 and ccs at the copper trafficking interface of these proteins. This binding suppresses copper trafficking, which leads to inhibition of cancer cell proliferation and tumor growth.
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences


03/17/16
20160073640 

Compositions comprising recombinant bacillus cells and another biological control agent


The present invention relates to a composition comprising a) recombinant exosporium-producing bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the bacillus cells; and b) at least one further biological control agent selected from particular microorganisms disclosed herein and/or a mutant of a specific strain of a microorganism disclosed herein having all identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts..
Bayer Cropscience Lp


03/10/16
20160069893 

Methods and compositions for analyzing proteins


Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs.
Monogram Biosciences, Inc.


03/10/16
20160069865 

Gm1 gangliosidosis human cell model and use thereof


In addition, the molecular symptoms of gm1 patient could be reproduced in the transformed cells having the e186a mutation which is newly identified as the gm1 gangliosidosis causing protein mutation. Therefore, the mutant cells containing the induced e186a mutation can be efficiently used as the gm1 gangliosidosis cell model..

03/10/16
20160068898 

Monitoring recombinase polymerase amplification mixtures


A process includes providing a mixture that includes a recombinase, a single-strand binding protein, and one or more oligonucleotides; and detecting particles in the reaction mixture.. .
Alere San Diego, Inc.


03/10/16
20160068861 

Method for detecting protein stability and uses thereof


Provided in the present invention is a genetic construct having a structure as represented by 5′-a+b+c+d+e-3′, wherein a indicates a promoter; b indicates a coding sequence of a fusion protein consisting of a target protein and a first labeled protein; c indicates a coding sequence of a connecting peptide; d indicates a coding sequence of a second labeled protein; and e indicates a terminator. Also provided in the present invention is a polypeptide having a structure as represented by b1+c1+d1, wherein b1 indicates the fusion protein consisting of the target protein and the first labelled protein; c1 indicates the connecting peptide; and d1 indicates a second labelled protein.
Shanghai Institutes For Bioligical Sciences, Chinese Academy Of Sciences


03/10/16
20160068829 

Antimicrobial fusion compounds and uses thereof


A fusion protein comprising at least one type 1 ribosome inactivating protein, polypeptide b; and at least one polypeptide a capable of viral entry inhibition; and/or at least one cationic antimicrobial peptide, polypeptide c.. .
Valiant Biopharma Sdn Bhd


03/10/16
20160068614 

Bonding tissues and cross-linking proteins with naphthalimide compounds


Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together.
Alumend, Llc


03/10/16
20160068580 

Method for treatment of gm1 gangliosidosis


In addition, the molecular symptoms of gm1 patient could be reproduced in the transformed cells having the e186a mutation which is newly identified as the gm1 gangliosidosis causing protein mutation. Therefore, the mutant cells containing the induced e186a mutation can be efficiently used as the gm1 gangliosidosis cell model..

03/10/16
20160067674 

Ligands and methods for isolating or removing proteins


The present disclosure relates generally to sorbents for binding proteins from blood plasma comprising a solid carrier material and an oligopeptide immobilized thereon, which selectively binds the protein from the blood plasma, and to a method for separating autologous proteins from blood plasma wherein the blood plasma is brought in contact with a corresponding sorbent, the desired protein is allowed to bind to the sorbent, the sorbent is separated from the plasma and the protein is subsequently separated from the sorbent. Corresponding sorbents and method allows for the selective isolation of specific blood plasma proteins directly from the blood plasma without having to conduct a tedious fractionation.
Previpharma Ag


03/10/16
20160067356 

Genetically modified human natural killer cell lines


The invention provides a natural killer cell, nk-92, modified to express an fc receptor on the surface of the cell, such as cd 16 (fcγriii-a), or other fcγ or fc receptors. The modified nk-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as fcεri-γ,tcr-ζ, or to concurrently express interleukin-2 (il-2) or other cytokines.
Fox Chase Cancer Center


03/10/16
20160067326 

Mutant bacteria for production of generalized modules for mrmbrane antigens


Gram-negative bacterial strains are generated by inactivating at least one lytm catalytic domain-containing protein, such as nt013, nt017 and nt022 of non typeable h influenzae. The vesicles from these strains are useful for vaccination..
Glaxosmithkline Biologicals S.a.


03/10/16
20160066611 

Process for preparing a pumpable broth composition


Disclosed here is a process for preparing a concentrated liquid composition (such as a broth) from poultry or other meat sources without the use of any enzymes. The resultant composition may have high content of solids but are pumpable or pourable and have relatively long shelf life at room temperature.
International Dehydrated Foods, Inc.


03/03/16
20160063177 

Automated computational enzyme identification and design


The invention provides computational methods for engineering, selecting, and/or identifying proteins with a desired activity. Further provided are automated computational design and screening methods to engineer proteins with desired functional activities including, but not limited to ligand binding, catalytic activity, substrate specificity, regioselectivity and/or stereoselectivity..

03/03/16
20160061847 

T2r taste receptors and genes encoding same


Newly identified mammalian taste-cell-specific g protein-coupled receptors and the genes encoding said receptors are described. Specifically, t2r taste g protein-coupled receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors.
Senomyx, Inc.


03/03/16
20160060671 

Synthon formation


This disclosure provides, among other things, a composition comprising: a 5′ exonuclease; a strand-displacing polymerase; and optionally a single strand dna binding protein and/or a ligase. A method for polynucleotide assembly to form a synthon, as well as a kit for performing the same, are also described..
New England Biolabs, Inc.


03/03/16
20160060662 

Desaturases of a green microalga and uses thereof


Isolated proteins which are at least partially encoded by polynucleotide sequences encoding novel desaturases are provided together with a composition which includes these isolated proteins. A transgenic plant, a transgenic alga, or a transgenic seed transformed by the polynucleotides encoding proteins which are at least partially encoded by novel desaturases are also provided.
Ben Gurion University Of The Negev Research And Development Authority


03/03/16
20160060656 

Methods and compositions for the treatment of lysosomal storage diseases


Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.. .
Sangamo Biosciences, Inc.


03/03/16
20160060642 

G protein coupled receptor libraries


The present invention relates to a yeast cell expressing a nematode g protein coupled receptor (gpcr), whereby ligand binding to the gpcr results in a detectable signal. In particular, the present invention relates to a yeast library expressing a range of different gpcrs, and to methods of screening said library..
Commonwealth Scientific And Industrial Research Organisation


03/03/16
20160060640 

Coryneform bacterium and producing heterologous fusion proteins


The present invention provides a coryneform bacterium having an ability to produce a heterologous fusion protein by secretory production, which has been modified to express a genetic construct for secretory production of the heterologous fusion protein encoding at least a heterologous fusion protein comprising an extein and an intein having an activity of acyl rearrangement. The method for producing proteins modified at the c-terminus is also provided..
Ajinomoto Co., Inc.


03/03/16
20160060591 

Feed media


The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods..
Amgen Inc.


03/03/16
20160060359 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


03/03/16
20160060358 

Induction of antigen-specific tolerance


Described are compositions and methods for the induction of an antigen-specific tolerance in a vertebrate. Also described are compositions and methods for the induction of antigen-specific tolerance using a fusion or a complex of the antigen (e.g., an antibody or an enzyme) against which tolerance is desired with a phosphatidylserine-binding domain derived from a phosphatidylserine-binding protein (including peptides)..
California Institute Of Technology


03/03/16
20160060341 

T-cell-specific humanized single fragment antibody delivery vehicle


The present invention relates to a humanized scfv delivery vehicle targeted to be human t-cell specific, and provides: a humanized scfv which comprises a heavy-chain variable region (vh) consisting of a polypeptide comprising an amino acid sequence given by sequence number 32 and comprises a light-chain variable region (vl) consisting of a polypeptide comprising an amino acid sequence given by sequence number 34; and a t-cell-specific drug or marker delivery vehicle comprising the humanized scfv. The humanized scfv of the present invention has minimalised antigenicity and has an effect which does not give rise to an immune reaction even when used in the human body, and thus can advantageously be used as a delivery vehicle for specifically delivering a target substance such as a sirna gene or an immune reaction regulating protein to t-cells..
(iucf-hyu (industry-university Cooperation Foundation Hanyang University)


03/03/16
20160060333 

Early marker of proteinuria in patients treated with an anti-vegf treatment


This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-vegf therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-vegf therapy has or is at risk for developing proteinuria or kidney injury are provided..
Mayo Foundation For Medical Education And Research


03/03/16
20160060332 

Therapeutic dll4 binding proteins


Improved dll4 binding proteins are described, including antibodies, cdr-grafted antibodies, human antibodies, and dll4 binding fragments thereof, proteins that bind dll4 with high affinity, and dll4 binding proteins that neutralize dll4 activity. The dll4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant dll4 expression or activity such as autoimmune disorders including multiple sclerosis..
Abbvie Inc.


03/03/16
20160060327 

Anti-infective binding proteins that bind aip2


There is disclosed compositions and methods relating to or derived from anti-aip2 antibodies. More specifically, there is disclosed fully human antibodies that bind aip2, aip2-binding fragments and derivatives of such antibodies, and aip2-binding polypeptides comprising such fragments.
Sorrento Tharapeutics, Inc.


03/03/16
20160060270 

New aryl-quinoline derivatives


Wherein r1, r2, r3, r4, r5, r6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (fabp) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases..

03/03/16
20160060260 

Bromodomain inhibitors for treating disease


Methods of inhibiting activity of a bromodomain-containing protein in a human or animal subject are also provided.. .

03/03/16
20160060235 

Therapeutic agent for type 2 diabetes


An object of the present invention is to provide a novel therapeutic agent for a patient with type 2 diabetes, a cause of which is the abnormal synthesis of insulin attributed to the abnormal modification of trnalys (uuu) in pancreatic β cells having cdkal1 gene mutation. The present inventors have used (1) a screening system using e.
Kumamoto Health Science University




G Protein topics: Antibodies, Nucleic Acid, G Proteins, Nucleic Acids, Amino Acid, Polypeptide, Protein A Affinity Chromatography, Chromatography, Chromatograph, Liver Metastasis, Membrane Protein, Colorectal Carcinoma, Rectal Carcinoma, Prophylactic, Glycoprotein

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.6674

4921

3 - 0 - 108